Left Ventricular Dysfunction With Pulmonary Hypertension

Slides:



Advertisements
Similar presentations
Pulmonary Hypertension
Advertisements

Congestive Heart Failure
Congestive Heart Failure
Diastolic Heart Failure, HFpEF, HFnEF: What are we treating anyway? Charles M. Rasmussen, MD FACC.
CHEST X-RAY FINDINGS: Left-to-Right Shunt
Pulmonary Hypertension and Congestive Heart Failure
Vascular Diseases of Lungs. Pulmonary Hypertension It is the increase in blood pressure in pulmonary arteries, veins and capillaries. It leads to shortness.
1 Cardiac Pathophysiology Part B. 2 Heart Failure The heart as a pump is insufficient to meet the metabolic requirements of tissues. Can be due to: –
Pulmonary Hypertension and Various Treatment Options
Dr. Meg-angela Christi M. Amores
Pathology of Pulmonary Hypertension Wolter J. Mooi Department of Pathology, VUmc Amsterdam
Respiratory Tutorial. Pulmonary oedema Causes –Haemodynamic Increased hydrostatic pressure –(heart failure, mitral stenosis, volume overload) Decreased.
Medical Progress: Heart Failure. Primary Targets of Treatment in Heart Failure. Treatment options for patients with heart failure affect the pathophysiological.
CHAPTER 6 DR. CARLOS ORTIZ BIO-208
Differentiate Pulmonary arterial hypertension from pulmonary venous congestion.
Hypertension Robbins: 525 to 530, Cecil:
PHARMACOLOGIC THERAPY  Standard First-Line Therapies Angiotensin-Converting Enzyme Inhibitors (ACEI) β Blockers Diuretics Digoxin  Second line Therapies.
Question 1 Which of the following is NOT true of the parasympathetic control of the heart? A. It affects muscarinic receptors. B. It decreases heart.
Date of download: 6/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cardio-Pulmonary-Renal Interactions: A Multidisciplinary.
Fig ACCF/AHA Guideline for the management of heart failure
Pharmacotherapy Of Cardiovascular Disorders: Heart Failure
From: Diabetic Retinopathy: Battling the Global Epidemic
Management of mitral regurgitation. See legend for Fig
Heart and Circulatory Failure
Copyright © 2015 by the American Osteopathic Association.
Hemodynamic classification of pulmonary hypertension (PH)
Normal physiology (control) is compared to that of acute mitral regurgitation (chordal rupture), compensated mitral regurgitation, and decompensated chronic.
Echocardiographic modalities for evaluation and risk stratification of heart failure patients. 3D indicates 3-dimensional; EF, ejection fraction; LA, left.
From: Pulmonary Atelectasis:A Pathogenic Perioperative Entity
Cirrhotic cardiomyopathy
Does a Vitamin D Boost Help in Resistant Hypertension Control?
Role of Right Ventricle and Dynamic Pulmonary Hypertension on Determining ΔVO2/ΔWork Rate FlatteningCLINICAL PERSPECTIVE by Francesco Bandera, Greta Generati,
Phase I Clinical Trial of Autologous Stem Cell–Sheet Transplantation Therapy for Treating Cardiomyopathy by Shigeru Miyagawa, Keitaro Domae, Yasushi Yoshikawa,
Chronic Vagus Nerve Stimulation Improves Autonomic Control and Attenuates Systemic Inflammation and Heart Failure Progression in a Canine High-Rate Pacing.
A, Breakdown of frailty into its underlying causes, manifestations, and clinical outcomes separated by LVAD-responsive and LVAD-independent causes of frailty.
Effect of intervention on diastolic function.
Potassium Channels and Proliferation of Vascular Smooth Muscle Cells
A Guide for the Perplexed
Menopause and Hypertension
The pathophysiology of myocardial infarction-induced heart failure
Meghan E. Sise, Andrew M. Courtwright, Richard N. Channick 
Cirrhotic cardiomyopathy
S. S. Pullamsetti, R. Savai, W. Janssen, B. K. Dahal, W. Seeger, F
Ragavendra R. Baliga, MD, MBA  Heart Failure Clinics 
Obesity and Heart Failure: Focus on the Obesity Paradox
Eugene Braunwald JCHF 2013;1:1-20
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Atrial Fibrillation: Beyond Rate Control
Wayne L. Miller et al. JCHF 2013;1:
Use of continuous flow ventricular assist devices in patients with heart failure and a normal ejection fraction: A computer-simulation study  Francesco.
Figure 1 Ventricular end-diastolic pressure–volume relationship curves
Vein graft failure Journal of Vascular Surgery
Pulmonary hypertension associated with left heart disease: Updated Recommendations of the Cologne Consensus Conference 2018  Stephan Rosenkranz, Irene.
Volume 74, Pages S19-S23 (December 2008)
Human Anatomy and Physiology II
Neal A. Chatterjee et al. JCHF 2014;2:
The molecular mechanisms of hemodialysis vascular access failure
Pulmonary Hypertension (PH)
Patrick O’Gara et al. JIMG 2008;1:
Definition of pulmonary hypertension (PH) associated with left heart disease. mPAP: mean pulmonary arterial pressure; PAWP: pulmonary artery wedge pressure;
Pro-inflammatory biomarkers in decompensated and stable HFpEF patients
Percentage distribution of ESC HF subtypes and no cardiac dysfunction (no dysf, n=38) among all 370 included patients, where HFvhd is HF due to valvular.
Medically Refractory Pulmonary Hypertension: Treatment With Nonpulsatile Left Ventricular Assist Devices  Christian D. Etz, MD, Henryk A. Welp, MD, Tony.
Rick A. Nishimura et al. JACC 2017;70:
Impaired Lung Function and Risk for Stroke
Algorithm for haemodynamic evaluation in the elderly.
Module 2: evaluation of the REVEAL risk score in the FPHN validation cohort. Module 2: evaluation of the REVEAL risk score in the FPHN validation cohort.
Prevention of stenosis after vascular reconstruction: Pharmacologic control of intimal hyperplasia—A review  Alexander W. Clowes, MD, Michael A. Reidy,
Christian Rask-Madsen, George L. King  Cell Metabolism 
Presentation transcript:

Left Ventricular Dysfunction With Pulmonary Hypertension by Vasiliki V. Georgiopoulou, Andreas P. Kalogeropoulos, Barry A. Borlaug, Mihai Gheorghiade, and Javed Butler Circ Heart Fail Volume 6(2):344-354 March 19, 2013 Copyright © American Heart Association, Inc. All rights reserved.

Types of pulmonary hypertension (PH) in patients with heart failure (HF). Types of pulmonary hypertension (PH) in patients with heart failure (HF). HTx indicates heart transplant; LVAD, left ventricular assist device; mPAP, mean pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; PDE, phosphodiesterase; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; and TPG, transpulmonary pressure gradient. Vasiliki V. Georgiopoulou et al. Circ Heart Fail. 2013;6:344-354 Copyright © American Heart Association, Inc. All rights reserved.

Pathophysiology of Group 2 pulmonary hypertension. Pathophysiology of Group 2 pulmonary hypertension. Left heart disease causes elevation of left atrial pressure, which in turn leads to increased hydrostatic pressure in pulmonary capillaries. Diastolic dysfunction is the main contributor of increased atrial pressure in heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and valvular heart disease. Mitral regurgitation and left ventricular (LV) hypertrophy contribute further to increased atrial pressure in HFrEF and valvular heart disease, respectively. Elevated hydrostatic pressure causes injury to the alveolar-capillary barrier in the acute phase, whereas chronically elevated pressure triggers various pathways involving the microcirculation and the alveolar wall. Mechanical injury because of hydrostatic pressure (alveolar-capillary stress failure) leads to disruption of the alveolar-capillary membrane, resulting in transition from interstitial leakage of protein (low permeability stage) to alveolar lumen leakage of protein and erythrocytes (high permeability stage). High permeability pulmonary edema activates matrix metalloproteinases (MMPs), causing degradation of matrix proteoglycan and alteration in the composition of membrane units, which in turn causes increased endothelial membrane fluidity. Initially, alveolar-capillary stress failure is a reversible phenomenon. However, chronic pressure elevation leads to remodeling and thickening (excessive collagen deposition) of the alveolar-capillary membrane, a process perpetuated by locally produced hormones (eg, angiotensin II [Ang II]) and inflammatory markers (eg, tumor necrosis factor-α [TNF-α]). The increased capillary pressure also promotes hypertrophy and fibrotic changes in the pulmonary arteries and veins with medial hypertrophy of smooth muscle cells (SMCs) and finally disruption of the elastic lamina. Imbalance in endothelin-1 (ET-1) and nitric oxide (NO) release and genetic factors influence these pulmonary vascular structural changes. EC indicates endothelial cell. Vasiliki V. Georgiopoulou et al. Circ Heart Fail. 2013;6:344-354 Copyright © American Heart Association, Inc. All rights reserved.